Chimeric Therapeutics Ltd has released a press release.
CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Positive pre-IND meeting with FDA for Phase 1 CAR T study
- Fourth dose cohort initiated in CHM 1101 Phase 1 trial
- Appendix 4D and Half Year Report
- Chimeric receives $3.06M R&D tax incentive
- Follow up period completed for 3rd cohort in CHM 1101 trial
Later from Chimeric Therapeutics
- Phase 1B brain cancer clinical trial approved for initiation
- New CLTX CAR technology patent protection in India & Israel
- Board & management commit to $1M placement and proposed spp
- SPP offer documents issued to shareholders
- Launch of new Phase 1B Glioblastoma clinical trial
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics